Mustang Bio, Inc. (MBIO) shareholders
Close on Nov 18, 2026Market cap $2.88MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Fortress Biotech, Inc. | 537,243 | 8.00% | 13D (active) amendment | Jan 2, 2026 |
| Daniel B. Asher Joint filing with Mitchell P. Kopin (8.80%), Intracoastal Capital LLC (8.80%) | 236,452 | 8.80% | 13G (passive) amendment | Mar 31, 2025 |
| Mitchell P. Kopin Joint filing with Daniel B. Asher (9.99%), Intracoastal Capital LLC (9.99%) | 186,552 | 9.99% | 13G (passive) | Feb 5, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Kestra Advisory Services, LLC | 196,991 | 2.60% | $138.29K | +20,949 | 0.00% |
| BlackRock, Inc. | 84,745 | 1.12% | $59.49K | – | 0.00% |
| Citadel Advisors LLC | 59,459 | 0.78% | $41.74K | +6,259 | 0.00% |
| Geode Capital Management, LLC | 42,240 | 0.56% | $29.65K | −50,550 | 0.00% |
| CFO4Life Group, LLC | 33,510 | 0.44% | $23.52K | +13,049 | 0.00% |
| Vanguard Fiduciary Trust Co | 32,120 | 0.42% | $22.55K | – | 0.00% |
| Vanguard Capital Management LLC | 25,704 | 0.34% | $18.04K | – | 0.00% |
| XTX Topco Ltd | 14,648 | 0.19% | $10.28K | New | 0.00% |
| Virtu Financial LLC | 14,356 | 0.19% | $10.00K | New | 0.00% |
| Two Sigma Securities, LLC | 13,742 | 0.18% | $9.65K | New | 0.00% |
| Susquehanna International Group, Llp | 13,664 | 0.18% | $9.59K | New | 0.00% |
| UBS Group AG | 4,155 | 0.05% | $2.92K | +496 | 0.00% |
| Tower Research Capital LLC (TRC) | 1,895 | 0.03% | $1.33K | – | 0.00% |
| Barclays PLC | 1,121 | 0.01% | $787 | New | 0.00% |
| SBI Securities Co., Ltd. | 509 | 0.01% | $357 | – | 0.00% |
| Morgan Stanley | 118 | 0.00% | $83 | – | 0.00% |
| Cullen/Frost Bankers, Inc. | 13 | 0.00% | $9 | – | 0.00% |
| Bnp Paribas Arbitrage, Snc | 6 | 0.00% | $4 | – | 0.00% |
| Nbc Securities, Inc. | 3 | 0.00% | $2 | – | 0.00% |
| JPMorgan Chase & Co | 2 | 0.00% | $1 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 23 | 1M | 7.1% | 5 / 4 | 1 / 3 | 0M | 0M |
| Q1 2026 | 22 | 1M | 6.7% | 4 / 5 | 4 / 6 | 0M | 0M |
| Q4 2025 | 25 | 1M | 7.3% | 7 / 6 | 4 / 2 | 0M | 0M |
| Q3 2025 | 20 | 0M | 3.7% | 6 / 6 | 3 / 3 | 0M | 0M |
| Q2 2025 | 17 | 0M | 1.0% | 3 / 4 | 3 / 2 | 0M | 0M |
| Q1 2025 | 16 | 0M | 1.5% | 2 / 7 | 5 / 16 | 0M | 0M |
| Q4 2024 | 30 | 0M | 1.2% | 11 / 6 | 4 / 6 | 0M | 0M |
| Q3 2024 | 25 | 0M | 0.2% | 5 / 5 | 4 / 7 | 0M | 0M |
| Q2 2024 | 29 | 0M | 0.2% | 9 / 6 | 5 / 10 | 0M | 0M |
| Q1 2024 | 30 | 0M | 0.2% | 6 / 6 | 7 / 4 | 0M | 0M |
| Q4 2023 | 28 | 0M | 0.3% | 4 / 6 | 4 / 3 | 0M | 0M |
| Q3 2023 | 27 | 0M | 0.2% | 4 / 3 | 6 / 4 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held MBIO in Q2 2026, 22% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 84,144 | 1.11% | $56.38K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 25,704 | 0.34% | $18.04K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 4,184 | 0.06% | $2.80K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 1,077 | 0.01% | $722 | 0.00% | May 31, 2026 |
| Nomura Healthcare Fund | 160 | 0.00% | $112 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Manuel Litchman MD | President, CEO and Interim CFO, Director | 1,615 | 0.02% | Apr 27, 2026 |
| Neil Herskowitz | Director | 145 | 0.00% | Dec 30, 2025 |
| Adam J. Chill | Director | 375 | 0.00% | Dec 30, 2025 |
| David Jin | Director | 286 | 0.00% | Dec 30, 2025 |
| Fortress Biotech, Inc. | 10% owner | 536,577 | 7.08% | Jan 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Manuel Litchman MD President, CEO and Interim CFO, Director | Apr 24, 2026 | Tax withholding | −19 | $0.75 | $14 | 1,615 |
| Fortress Biotech, Inc. 10% owner | Jan 2, 2026 | Award | +278,385 | – | – | 536,577 |
| David Jin Director | Dec 30, 2025 | Buy | +247 | $0.96 | $237 | 286 |
| Neil Herskowitz Director | Dec 30, 2025 | Sale | −247 | $0.96 | $237 | 145 |
| Adam J. Chill Director | Dec 30, 2025 | Sale | −4 | $0.95 | $4 | 375 |
| Fortress Biotech, Inc. 10% owner | Sep 29, 2025 | Award | +59,334 | – | – | 258,192 |
| Manuel Litchman MD President, CEO and Interim CFO, Director | Apr 24, 2025 | Tax withholding | −27 | $1.24 | $33 | 1,634 |
| Fortress Biotech, Inc. 10% owner | Mar 31, 2025 | Award | +67,806 | – | – | 198,858 |
| Fortress Biotech, Inc. 10% owner | Jun 27, 2024 | Award | +575,191 | – | – | 2,502,991 |
| Manuel Litchman MD President and CEO, Director | May 31, 2024 | Tax withholding | −1,396 | $0.35 | $489 | 83,024 |
| Fortress Biotech, Inc. 10% owner | Jan 2, 2024 | Award | +419,092 | – | – | 1,927,800 |
| Adam J. Chill Director | Jul 5, 2023 | Award | +7,246 | – | – | 19,170 |
| Neil Herskowitz Director | Jul 5, 2023 | Award | +7,246 | – | – | 19,703 |
| Lindsay A. Rosenwald Md Director | Jul 5, 2023 | Award | +7,246 | – | – | 60,525 |
| Michael S. Weiss Director | Jul 5, 2023 | Award | +7,246 | – | – | 49,637 |
| Michael J. Zelefsky Director | Jul 5, 2023 | Award | +7,246 | – | – | 18,970 |
| Manuel Litchman MD President and CEO, Director | Apr 24, 2023 | Tax withholding | −1,572 | $4.21 | $6.62K | 79,420 |
| Manuel Litchman MD President and CEO, Director | Apr 24, 2023 | Award | +5,000 | – | – | 111,079 |
| Fortress Biotech, Inc. 10% owner | Jan 6, 2023 | Award | +2,807,008 | – | – | 22,630,620 |
| Manuel Litchman MD Director | Sep 13, 2022 | Buy | +5,000 | $0.52 | $2.60K | 1,098,987 |
| Lindsay A. Rosenwald Md Director | Sep 13, 2022 | Buy | +5,000 | $0.52 | $2.60K | 299,181 |
| Michael J. Zelefsky Director | Jul 29, 2022 | Award | +71,664 | – | – | 175,861 |
| Adam J. Chill Director | Jul 29, 2022 | Award | +71,664 | – | – | 178,861 |
| Neil Herskowitz Director | Jul 29, 2022 | Award | +71,664 | – | – | 186,861 |
| Michael S. Weiss Director | Jul 29, 2022 | Award | +71,664 | – | – | 135,861 |
| Lindsay A. Rosenwald Md Director | Jul 29, 2022 | Award | +71,664 | – | – | 294,181 |
| Manuel Litchman MD Director | Jun 21, 2022 | Award | +61,000 | – | – | 1,093,987 |
| Manuel Litchman MD President and CEO, Director | Apr 24, 2022 | Tax withholding | −1,248 | $12.15 | $15.16K | 80,992 |
| Manuel Litchman MD Director | Mar 18, 2022 | Buy | +5,000 | $0.74 | $3.70K | 1,032,987 |
| Lindsay A. Rosenwald Md Director | Mar 18, 2022 | Buy | +4,094 | $0.74 | $3.03K | 222,517 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Dec 14, 2021 | Sale | −4,374 | $1.83 | $8.00K | 144,729 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Dec 8, 2021 | Award | +22,500 | – | – | 149,103 |
| Manuel Litchman MD President and CEO, Director | Oct 27, 2021 | Buy | +65,000 | $2.24 | $145.60K | 1,027,987 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Oct 12, 2021 | Sale | −4,450 | $2.28 | $10.15K | 126,603 |
| Lindsay A. Rosenwald Md Director | Aug 31, 2021 | Award | +1,170 | $2.58 | $3.02K | 218,423 |
| Manuel Litchman MD President and CEO, Director | Aug 31, 2021 | Award | +2,746 | $2.58 | $7.08K | 962,987 |
| Manuel Litchman MD President and CEO, Director | Jul 30, 2021 | Buy | +86,206 | $2.91 | $250.86K | 960,241 |
| Michael S. Weiss Director | Jun 28, 2021 | Award | +13,774 | – | – | 64,197 |
| Lindsay A. Rosenwald Md Director | Jun 28, 2021 | Award | +13,774 | – | – | 217,253 |
| Neil Herskowitz Director | Jun 28, 2021 | Award | +13,774 | – | – | 115,197 |
| Adam J. Chill Director | Jun 28, 2021 | Award | +13,774 | – | – | 107,197 |
| Michael J. Zelefsky Director | Jun 28, 2021 | Award | +13,774 | – | – | 104,197 |
| Manuel Litchman MD President and CEO, Director | Jun 17, 2021 | Award | +61,000 | – | – | 874,035 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Apr 9, 2021 | Sale | −2,423 | $3.36 | $8.14K | 131,053 |
| Manuel Litchman MD President and CEO, Director | Mar 5, 2021 | Buy | +165,562 | $3.12 | $516.55K | 825,408 |
| Manuel Litchman MD President and CEO, Director | Feb 26, 2021 | Award | +5,000 | $2.83 | $14.15K | 659,846 |
| Lindsay A. Rosenwald Md Director | Feb 26, 2021 | Award | +1,043 | $2.83 | $2.95K | 203,479 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Dec 15, 2020 | Award | +22,500 | – | – | 151,774 |
| Manuel Litchman MD President and CEO, Director | Dec 15, 2020 | Buy | +100,000 | $2.91 | $291.00K | 654,846 |
| Lindsay A. Rosenwald Md Director | Dec 14, 2020 | Buy | +100,000 | $2.66 | $266.00K | 202,436 |
| Lindsay A. Rosenwald Md Director | Dec 14, 2020 | Buy | +100,000 | $2.66 | $266.00K | 200,423 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Dec 8, 2020 | Sale | −5,185 | $3.03 | $15.71K | 133,476 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Oct 21, 2020 | Sale | −3,056 | $2.97 | $9.08K | 138,661 |
| Manuel Litchman MD President and CEO, Director | Sep 15, 2020 | Award | +61,000 | – | – | 554,846 |
| Lindsay A. Rosenwald Md Director | Aug 31, 2020 | Award | +1,182 | $2.48 | $2.93K | 102,436 |
| Manuel Litchman MD President and CEO, Director | Aug 31, 2020 | Award | +5,000 | $2.48 | $12.40K | 493,846 |
| Lindsay A. Rosenwald Md Director | Jul 14, 2020 | Award | +16,611 | $2.48 | $41.20K | 101,254 |
| Neil Herskowitz Director | Jul 14, 2020 | Award | +16,611 | – | – | 101,423 |
| Lindsay A. Rosenwald Md Director | Jul 14, 2020 | Award | +16,611 | – | – | 100,423 |
| Adam J. Chill Director | Jul 14, 2020 | Award | +16,611 | – | – | 93,423 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Mustang Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,206 shares on Sep 8, 2026 over the last 90 days.
See a number that looks wrong?